Endpoints News – Biotech and pharma business news, with a focus …
All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs. SIGN UP NOW
Endpoints News – Biotech and pharma business news, with a focus …
The FDA has approved Xcovery Holdings' ALK inhibitor Ensacove for first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive locally advanced or ...
Endpoints winners and losers 2024: Best and worst biotech trends
Dec 19, 2024 · Endpoints News reviews 2024's biopharma winners & losers: Eli Lilly dominates obesity market, megadeals decline, I&I sector thrives, and FDA's setback in misinformation fight.
Endpoints at #BIO23: The dawn of a new biotech era
The dawn of a new biotech era. The biotech industry’s annual trade conference is back in Boston. We assess where we are as an industry and break down the future trends in biopharma.
The Endpoints 100 survey: What are biopharma execs saying …
Dec 11, 2024 · We’ve asked our advisory group in the E100 about how things are shaping up at the FDA and HHS under the new Trump administration and what impact prospective changes could have on the drug development industry. Also, they have insights on the tense China-US relations and drug development, AI and our continuing focus on financing at …
ESMO23 | Cancer breakthroughs and barriers in oncology R&D
Endpoints is on the ground at ESMO this year and the lineup will be one to watch — what drugs in the cancer pipeline show promise? Which ones won’t make it past the goal line? Join us as we break down the highlights and readouts with our expert roundtable moderated by Endpoints journalists and more. Tune in online as our team reports from …
2024’s biopharma winners and losers; CagriSema falls short; Merck ...
6 days ago · Endpoints Weekly reports newsletter break Dec 24-Jan 2. Highlights: Novo's CagriSema data disappoints, Merck licenses GLP-1 from Hansoh Pharma, and Trump's FTC picks show less pharma focus.
Endpoints 11 - Biopharma's Most Promising Startups in 2021
Sep 22, 2024 · The startup world in biotech has changed radically in the last few years. Now, the right scientists teamed with the right execs can raise hundreds of millions of dollars to back biotechs that are looking to develop breakthrough drugs with game-changing technology.
Endpoints at #JPM25 - January 13-14, 2025 - San Francisco
In the biopharma world, the new year doesn’t start on January 1 — it starts when the industry descends on San Francisco for JPM. Dealmakers, investors, and corporate leaders will gather to chart the course for 2025 and take stock of the landscape, both financial and political.
Endpoints at #ESMO24
Sep 17, 2024 · ESMO is the oncology conference to watch this year — the Endpoints team is on the ground reporting on the latest readouts and pipeline updates from the European cancer drug scene. What pathways and targets show promise? Will practice-changing data readouts upend the competitive landscape? We’re making sense of the trove of data dropped with our experts.